Chardan Capital Reaffirms “Buy” Rating for Monopar Therapeutics (NASDAQ:MNPR)

Monopar Therapeutics (NASDAQ:MNPR)‘s stock had its “buy” rating reaffirmed by analysts at Chardan Capital in a research note issued on Monday,Benzinga reports. They currently have a $100.00 price target on the stock. Chardan Capital’s target price suggests a potential upside of 84.84% from the stock’s previous close.

Several other analysts have also recently commented on MNPR. Morgan Stanley initiated coverage on shares of Monopar Therapeutics in a report on Friday, January 9th. They set an “overweight” rating and a $115.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Thursday, January 22nd. BTIG Research restated a “buy” rating and set a $104.00 price target on shares of Monopar Therapeutics in a report on Monday, February 23rd. Wall Street Zen lowered Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $107.00.

Monopar Therapeutics Price Performance

MNPR stock opened at $54.10 on Monday. Monopar Therapeutics has a 52-week low of $26.06 and a 52-week high of $105.00. The company’s 50 day simple moving average is $59.62 and its 200-day simple moving average is $70.95. The firm has a market capitalization of $361.55 million, a P/E ratio of -29.73 and a beta of 1.58.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Friday, March 27th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.10). Sell-side analysts predict that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Institutional Trading of Monopar Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP bought a new stake in Monopar Therapeutics in the third quarter valued at $18,904,000. Siren L.L.C. bought a new position in shares of Monopar Therapeutics during the fourth quarter valued at $13,863,000. Deerfield Management Company L.P. acquired a new stake in shares of Monopar Therapeutics in the 3rd quarter valued at $13,048,000. RA Capital Management L.P. boosted its stake in shares of Monopar Therapeutics by 30.5% in the 4th quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock valued at $43,569,000 after purchasing an additional 156,000 shares in the last quarter. Finally, TCG Crossover Management LLC bought a new stake in shares of Monopar Therapeutics in the 3rd quarter worth about $12,496,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.